Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 11/20 | 0.48 |
| ▸ | HRH1 | P35367 | 11/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095370 | 1.00 | HRH2 (0.48) | HRH2HRH1HRH3MEN1DRD3 | |
| SCHEMBL6094259 | 0.89 | POLB (0.54) | HRH2HRH1HRH3MEN1DRD3 | |
| SCHEMBL6094254 | 0.89 | POLB (0.54) | HRH2HRH1HRH3MEN1DRD3 | |
| SCHEMBL6095366 | 0.86 | DRD3 (0.60) | HRH2HRH1HRH3MEN1DRD3 | |
| SCHEMBL7035874 | 0.83 | POLB (0.52) | HRH2HRH1HRH3MEN1POLB | |
| SCHEMBL2964372 | 0.82 | KCNH2 (0.63) | HRH2HRH1HRH3MEN1POLB | |
| SCHEMBL5965484 | 0.80 | POLB (0.51) | HRH2HRH1HRH3MEN1DRD3 | |
| SCHEMBL6094368 | 0.80 | HRH3 (0.45) | HRH2HRH1HRH3MEN1POLB | |
| SCHEMBL7098324 | 0.80 | HRH3 (0.45) | HRH2HRH1HRH3MEN1POLB | |
| SCHEMBL6094373 | 0.80 | HRH3 (0.45) | HRH2HRH1HRH3MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HRH2 2122/4885HRH1 2707/4885HRH3 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.